Cardiff Oncology, Inc.
NASDAQ:CRDFBiotechnology
+$0.03 today
- Market cap
- $65.27M
- Beta
- 1.38
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$0.65
Volume 0.86M
Average 1.05M
CRDF Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Cardiff Oncology, Inc.NASDAQ: CRDF
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity falls 51.0% from a year ago
Total equity stood at $34.71M at the end of Q1 FY2026, down 51.0% from a year earlier and down 23.5% from the prior quarter. Over 3 fiscal years it compounded at -24.7% a year.
Context
- Total equity amounted to 70.6% of total assets at the end of Q1 FY2026, down 13.0 pp from a year earlier.
- Total equity increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps falling in the next quarterly balance sheet after a -51.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 45.39M USD
- Year-over-year change
- -45.3%
- 4-year CAGR
- -24.6%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 45.39M | -45.3% |
| FY2024 | 2024-12-31 | 82.95M | +18.9% |
| FY2023 | 2023-12-31 | 69.74M | -34.4% |
| FY2022 | 2022-12-31 | 106.34M | -24.3% |
| FY2021 | 2021-12-31 | 140.42M | — |
Total Equity vs competitors
How CRDF compares with its peers on the latest reported figures
- Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -51.0% is the 7th highest of 9, against a peer median of +4.5%.
- Total equity amounts to 70.6% of total assets for CRDF, versus a peer median of 65.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $133.98M USD | +45.9% | -6.4% | 85.7% | |
| Mar 2026 | $126.34M USD | -0.6% | +64.7% | 87.4% | |
| Mar 2026 | CHF 68.25M CHF | -46.8% | -30.1% | 78.1% | |
| Mar 2026 | $42.1M USD | +9.6% | +16.3% | 62.6% | |
| Mar 2026 | $36.05M USD | +688.7% | -14.3% | 18.6% | |
| Mar 2026 | $35.54M USD | +764.5% | -17.5% | 68.5% | |
| Mar 2026 | $34.71M USD | -51.0% | -24.7% | 70.6% | |
ELTXElicio Therapeutics, Inc. | Mar 2026 | -$1.44M USD | -116.1% | -43.2% | 6.3% |
| Dec 2025 | -€21.69M EUR | -345.6% | — | 34.6% | |
| Peer median (excluding CRDF) | — | +4.5% | -14.3% | 65.6% | |
Competitors are the stored peer set for CRDF. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 11.94M | 16.35M | 21.66M | 51.47M | 17.47M |
| Short-term Investments | 128.88M | 88.92M | 53.17M | 40.28M | 40.83M |
| Net Receivables | 535K | 771K | 288K | 773K | 182K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 5.25M | 2.3M | 2.54M | 1.64M |
| Total Current Assets | 146.13M | 111.28M | 77.41M | 95.05M | 60.13M |
| Property, Plant & Equipment (Net) | 3.18M | 3.52M | 2.95M | 2.07M | 1.21M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 239K | 1.39M | 1.28M | 69K | 549K |
| Total Non-current Assets | 3.42M | 4.91M | 4.23M | 2.14M | 1.76M |
| Total Assets | 149.54M | 116.19M | 81.64M | 97.19M | 61.88M |
| Account Payables | 1.44M | 1.96M | 1.97M | 4.82M | 8.09M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.48M | 1.85M | 5.05M | 2.75M | 2.43M |
| Total Current Liabilities | 6.56M | 7.81M | 10.44M | 13.43M | 16.39M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 2.57M | 2.04M | 1.46M | 813K | 102K |
| Total Liabilities | 9.13M | 9.85M | 11.9M | 14.24M | 16.5M |
| Common Stock | 4K | 4K | 4K | 7K | 7K |
| Retained Earnings | (259.81M) | (298.1M) | (339.54M) | (384.18M) | (430.03M) |
| Accumulated OCI | (142K) | (395K) | (67K) | 34K | 50K |
| Other Stockholders Equity | (139K) | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 140.42M | 106.34M | 69.74M | 82.95M | 45.39M |
| Total Debt | 3.12M | 2.72M | 2.15M | 1.52M | 832K |
| Net Debt | (8.82M) | (13.63M) | (19.51M) | (49.95M) | (16.64M) |
Cardiff Oncology, Inc.
NASDAQ:CRDF
Intrinsic Alpha fair value
Locked
Current Price
$0.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.